Aiosyn, a medical software company that develops AI-powered pathology solutions, has been awarded a EUR 1.300.000 EFRO-OOST grant alongside Radboud university medical center and Pathologie-DNA to accelerate the development of AI technology for breast and skin cancer diagnostics.
IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the first quarter ended March 31, 2023.
BrainStorm Cell Therapeutics Inc. announced that it will hold a conference call to update shareholders on financial results for the First Quarter ended March 31, 2023, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, May 15th.
On April 22, Neuboron Medical Group, a leading global Accelerator-based Boron Neutron Capture Therapy total solution provider, and Xiamen Humanity Hospital collaborated to co-host the Xiamen BNCT Technology Forum 2023 at the BNCT center in XHH.
El Efecto Mandela consiste en una situación en la que hay diversas personas que creen que ocurrió un evento, pero no fue de esa manera, siendo un fenómeno que puede observarse en acontecimientos históricos, películas, series de televisión, entre ot …
Diagnostic company SphingoTec has been successfully re-certified according to ISO 13485 and received its first IVDR certificate for its IVD product sphingotest® penKid®.
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041.
Ochre Bio, an innovator in chronic liver disease medicine development, has announced its participation in upcoming investor and industry conferences, sharing expert perspectives and insights across liver disease and RNA therapeutics, building and scaling startups, and the future of medicine.
Ochre Bio to Participate in Upcoming Global Industry Conferences – May 09, 2023 Read More »
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s supplemental Biologics License Application for Vabysmo® for the treatment of macular edema following retinal vein occlusion.
Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced a manufacturing partnership with WuXi Advanced Therapies, a global Contract Testing, Development and Manufacturing Organization.
